GlaxoSmithKline’s years-long oncology resurgence is on track to have two new drugs approved in the US in mid-2020, after the company won a key first-line ovarian cancer indication for Zejula (niraparib) in April. The belantamab mafodotin and dostarlimab approvals also anticipated this year will give GSK its first commercial footholds in the immuno-oncology market – one of four cancer drug categories where the company is developing new therapies.
“We have been a little bit in the shadows and are just getting into the spotlight with some of the more recent work that we’ve made public,” GSK (NYSE: GSK) senior vice… Read more »
UNDERWRITERS AND PARTNERS
